Cantor Fitzgerald Reiterates Neutral on Regeneron Pharmaceuticals, Maintains $1015 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer has reiterated a Neutral rating for Regeneron Pharmaceuticals, maintaining a price target of $1015.
September 16, 2024 | 4:59 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Cantor Fitzgerald has reiterated a Neutral rating for Regeneron Pharmaceuticals, keeping the price target at $1015. This suggests that the analyst does not expect significant short-term price movement.
The reiteration of a Neutral rating and maintenance of the price target at $1015 by Cantor Fitzgerald indicates that the analyst does not foresee significant changes in Regeneron's stock price in the short term. This suggests stability rather than volatility.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100